AbilityPharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies that induce autophagy to selectively kill cancer cells. Their lead drug candidate, ABTL0812, is in phase 2b clinical trials for pancreatic cancer and has shown promising results in other cancers, including endometrial and lung cancer. The company's approach represents a novel therapeutic strategy in oncology, aiming to address unmet medical needs with high efficacy and safety.

Basic information

Country

SPAIN

Group Name

AbilityPharma

Source

Source